The 2025-2030 World Outlook for Human Microbiome Therapeutics

The 2025-2030 World Outlook for Human Microbiome Therapeutics

This study covers the world outlook for human microbiome therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of human microbiome therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 4D Pharma, AbbVie S.à.r.l., Accinov, ActoGeniX, Aju IB Investment, Ally Bridge Group, Amrita Therapeutics, AOBiome, AquaBounty Technologies, Arctic Aurora Life Science, Aspire Capital Fund, Assembly Biosciences, Azitra, Baseclear, BIOASTER, Biological & Popular Culture, Inc., BiomX, Bio-Technology General, Blue Turtle Bio, Bristol-Myers Squibb, BYTC Corporation, C3J Therapeutics, Caelus Health, Cd4 Biosciences, Inc., Cedars-Sinai Medical Centre, Chengdu Sen Nuo Wei Biotechnology Company, Ltd., CLI Ventures, Codexis Laboratories Hungary KFT, CoreBiome, Crestovo, CRS Bio, Inc., DayTwo, Digitalis Ventures, Effective Pharmaceuticals, Inc., Enterome, EnviroFlight, Epibiome, Epitope Pharmaceuticals, Inc., Evelo Biosciences, Evolve Biosystems, Ferring Pharmaceuticals, Finch Therapeutics, Genomatix, Ltd., Genten Therapeutics, Inc., GenVec, Global Bioscience Company, GT Biologics, Ltd., Hartlab, LLC, Harvest Capital Strategies, LLC, HealthMine, IBBL, iCarbonX, Igen Biotech Group, ImmuneBiotech AB, Immuron, INC Research, INRA Transfer, Intrexon, Janssen Biotech, Johnson & Johnson, Kallyope, Kolu Pohaku Management, LLC, Leading BioSciences, LNC Therapeutics, Lundbeckfond Ventures, MaaT Pharma SA, MATRISYS BIOSCIENCE, Mayo Clinic, Medistem, Medpace, Merck & Company, MICROBIOME THERAPEUTICS, Microbiomics, Ltd., Mirna Therapeutics, Nestle Health Science, Nitrocell, NIZO, Nubiyota, NuMe Health, LLC, Okanagan Specialty Fruits, Inc., Omnes Capital, Openbiome, Optibiotix Health, OrbiMed HealthCare Fund Management, Osel, OvaXon, LLC, Oxitec, Perceptive Advisors, Pfizer Venture Investments, Pharm-Olam International, Pipex Therapeutics, Inc., PRECIGEN, Prev AbR, LLC, ProDigest, Puretech Health, Putney Drug Corporation, Pylum Biosciences, Quorum Innovations, Rebiotix, Ritter Natural Sciences, LLC, Roche Venture Fund, Rock Springs Capital, S & I Ophthalmic, Second Genome, Seres Therapeutics, Seventure Partners, Shire, Solovax, Inc., SR One Venture Partners, Symberix, Symbiotic Health, Symbiotix Biotherapies, Synlogic, Synthetic Biologics, Takeda, TargEDys, Tech Coast Angels (TCA), The Microbiota Company, Ltd., Trans Ova Genetics LC, Tucana Health, Ltd., Vedanta Biosciences, Veristat, Vertex Pharmaceuticals, Whole Biome, and Xycrobe Therapeutics. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).